Evidence map›Paper›PMID 37140213›Full record

Observational studyCancer medicine2023

Fifteen-year survival and conditional survival of women with breast cancer in Osaka, Japan: A population-based study.

Mizuki Kato, Kayo Nakata, Toshitaka Morishima, Yoshihiro Kuwabara, Fumie Fujisawa, Nobuyoshi Kittaka, Takahiro Nakayama, Isao Miyashiro

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mizuki KatoCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0002-7728-8853
Kayo NakataCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0001-9782-8637
Toshitaka MorishimaCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0002-0747-3287
Yoshihiro KuwabaraCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0003-4161-2970
Fumie FujisawaDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0001-8436-9072
Nobuyoshi KittakaDepartment of Breast Surgery, Osaka Rosai Hospital, Osaka, Japan.ORCID 0000-0002-0906-1155
Takahiro NakayamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0002-3713-1624
Isao MiyashiroCancer Control Center, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0002-2575-4971
Osaka International Cancer Institute · JPOsaka Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, the survival of patients with breast cancer has improved. However, few published studies have a longer than 10-year follow-up. Conditional relative survival (CRS), which is relative survival (RS) of patients who have survived beyond a certain period after diagnosis, is useful for assessing excess mortality among long-term survivors compared with the general population.

methodsThis was a retrospective observational cohort study. Population-based cancer registry data in Osaka, Japan were used to determine 15-year RS and 5-year CRS of women with breast cancer diagnosed between 2001 and 2002 and followed up for at least 15 years. Fifteen-year RS and age-standardized RS (ASR) were calculated by Ederer II and cohort methods. Five-year CRS according to age group and extent of disease (localized, regional, and distant) was estimated for every year from diagnosis to 10 years.

resultsIn the cohort of 4006 patients, the ASR declined progressively, the 5-year ASR being 85.8%, 10-year ASR 77.3%, and 15-year ASR 71.6%. The overall 5-year CRS exceeded 90% at 5 years after diagnosis, reflecting a small excess mortality compared with the general population. The 5-year CRS of patients with regional and distant disease did not reach 90% within 10 years of follow-up (89.4% for regional and 72.9% for distant disease 10 years after diagnosis), indicating that these patients had substantial excess mortality.

conclusionLong-term survival data can help cancer survivors plan their lives and receive better medical care and support.

Indexed as

Breast NeoplasmsCancer SurvivorsCohort StudiesFemaleHumansJapanRegistriesSurvival RateSurvivorsbreast cancerepidemiologysurvivalwomen's cancer

Identifiers

PMID37140213
PMCPMC10315741
OpenAlexW4368355746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.